In a prospective cohort study of 183 enrolled patients with IBD, treatment with anti-TNF agents or vedolizumab resulted in improvement of depression, sleep and anxiety within 6 weeks of initiation of treatment up until one year or more [148]. Here, TNF is linked to inflammatory bowel disease.